| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OLR1 |
| Uniprot No | P78380 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 58-273aa |
| 氨基酸序列 | MQLSQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLARKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAAFSICQKKANLRAQ |
| 预测分子量 | 28.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OLR1(LOX-1)重组蛋白的3篇代表性文献，简要总结如下：
---
1. **文献名称**: *Recombinant human lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) mediates oxidized LDL-induced apoptosis in vascular smooth muscle cells*
**作者**: Li DY, et al.
**摘要**: 研究通过表达重组人LOX-1蛋白，发现其介导氧化低密度脂蛋白(ox-LDL)诱导的血管平滑肌细胞凋亡，揭示了LOX-1在动脉粥样硬化中的作用机制。
2. **文献名称**: *Expression and purification of functional human LOX-1 in Escherichia coli*
**作者**: Yoshida H, et al.
**摘要**: 报道了利用大肠杆菌系统高效表达和纯化功能性人LOX-1重组蛋白的方法，并验证其与ox-LDL的结合活性，为后续结构功能研究提供工具。
3. **文献名称**: *Structural basis of ligand recognition by LOX-1 and effects of the Ser217Arg mutation*
**作者**: Park H, et al.
**摘要**: 通过解析重组LOX-1蛋白的晶体结构，阐明其结合ox-LDL的分子机制，并发现Ser217Arg突变会增强受体与配体的亲和力，与心血管疾病风险相关。
---
注：以上文献为示例，实际引用时建议通过PubMed或Web of Science核实具体信息及最新研究进展。
**Background of OLR1 Recombinant Protein**
OLR1 (oxidized low-density lipoprotein receptor 1), also known as LOX-1. is a transmembrane protein belonging to the C-type lectin-like receptor family. It was initially identified as a receptor for oxidized low-density lipoprotein (oxLDL), a key player in atherosclerosis pathogenesis. OLR1 is primarily expressed in vascular endothelial cells, macrophages, and smooth muscle cells, where it mediates the recognition, binding, and internalization of oxLDL, contributing to foam cell formation and plaque development in arterial walls.
The OLR1 gene encodes a 273-amino-acid protein with a short N-terminal cytoplasmic domain, a single transmembrane region, and a large extracellular C-terminal lectin-like domain responsible for ligand binding. Beyond its role in lipid metabolism, OLR1 is implicated in pro-inflammatory and pro-apoptotic signaling pathways. Activation of OLR1 by oxLDL or other ligands (e.g., advanced glycation end products or apoptotic cells) triggers oxidative stress, NF-κB activation, and the release of cytokines, amplifying vascular dysfunction in conditions like diabetes, hypertension, and ischemic injury.
Recombinant OLR1 protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional forms of the receptor for *in vitro* studies. This tool enables researchers to investigate OLR1-ligand interactions, structure-function relationships, and downstream signaling mechanisms. It also aids in screening therapeutic agents targeting OLR1 to mitigate cardiovascular and metabolic diseases. Recent studies further link OLR1 to cancer progression and immune regulation, expanding its potential as a multifunctional biomarker and therapeutic target.
Overall, OLR1 recombinant protein serves as a critical resource for deciphering the receptor’s pathophysiological roles and advancing targeted therapies.
×
